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compounds for the yeast enzyme. However, since the
amino acid sequence of yeast hexokinase was still un-
known when its crystal structure in complex with OTG
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1Groupe de Chimie Organique Biologique was solved, major uncertainties existed with respect to
the actual residues involved in the enzyme’s active site.Laboratoire Synthe`se Physico-Chimie
des Mole´cules d’Inte´reˆt Biologique A better understanding of the interactions of a glucose
analog with the active-site residues was obtained afterUMR-CNRS-5068
Universite´ Paul Sabatier a complete rebuilding of the yeast hexokinase structure
by using its primary structure when it became available31062 Toulouse Cedex
2 Centre de Recherche Paul Pascal [3]. Moreover, hexokinase undergoes a considerable
conformational change during its catalytic cycle [4], andUPR-CNRS-8641
Universite´ de Bordeaux further information on the extent of hinge bending of
the enzyme was then obtained by FTIR analysis [5]. In33600 Pessac
France this paper, we extend our studies to the hexokinase of
Trypanosoma brucei, a blood-dwelling protozoan para-3 Research Unit for Tropical Diseases
Christian de Duve Institute of Cellular Pathology site responsible for human sleeping sickness in Africa.
In the blood of the mammalian host, the parasite hasand Laboratory of Biochemistry
Universite´ Catholique de Louvain access to an unlimited source of glucose, which is main-
tained at a relatively constant concentration of 5 mM.Brussels
Belgium Glucose is the major substrate for energy metabolism
in T. brucei, since its mitochondrial metabolism is com-
pletely repressed. As a consequence, the Embden-Mey-
erhoff pathway of glycolysis serves as the sole sourceSummary
of ATP for the parasite [6], which renders the enzymes
of the pathway attractive targets for drug intervention.For Trypanosoma brucei, a parasite responsible for
African sleeping sickness, carbohydrate metabolism Moreover, the organization of the glycolytic pathway in
the trypanosome differs from that in the host in thatis the only source of ATP, and glycolytic enzymes are
localized within membrane-bound organelles called the first seven enzymes are localized within membrane-
bounded organelles called glycosomes [7]. In theseglycosomes. Hexokinase, the first enzyme of the gly-
colytic pathway, was chosen as a target for selective highly specialized microbodies, hexokinase, the first en-
zyme of the glycolytic pathway, catalyses the transferdrug design. We have cloned and sequenced the hexo-
kinase gene of T. brucei. In parallel, we have synthe- of the  phosphoryl group of ATP to a glucose molecule.
Almost all glucose 6-phosphate so formed is metabo-sized several inhibitors. Kinetic analysis revealed dif-
ferences in the binding mode of these compounds lized by the glycolytic pathway, allowing for the synthe-
sis of ATP, whereas the remainder enters the pentose-toward yeast and T. brucei hexokinases, while the
m-bromophenyl glucosamide was found to be selec- phosphate pathway for the synthesis of NADPH and
the precursors of nucleic acids. Thus, any inhibition oftive for T. brucei. The modeled structure of T. brucei
hexokinase-inhibitor complex (using the crystal struc- hexokinase would directly interfere with the formation of
both ATP and nucleic acid precursors. The trypanosometure of the Schistosoma mansoni hexokinase as a tem-
plate) allows us to propose a mode of action of this enzyme differs from the host enzyme (36%–37% identity
with the three human hexokinase isoenzymes) in that itinhibitor for the trypanosome hexokinase and to ac-
count for the observed selectivity. is not inhibited by glucose 6-phosphate. The latter is
also twice as large as what has been attributed to a
gene duplication that would have taken place duringIntroduction
vertebrate evolution [8, 9]. These features render the
trypanosome hexokinase an interesting target for selec-Previously, we have studied the inhibition of yeast hexo-
tive drug design.kinase by a series of analogs of glucosamine, a well-
For the design of inhibitors, we reasoned as follows:known competitive inhibitor of hexokinase [1]. This
(1) compounds should be derivatives of glucosamine,study was aided by the availability of a crystal structure
to maintain a high degree of similarity with glucose; (2)of a complex between the yeast hexokinase and ortho-
substitution should only be at the C2 position on thetoluyl-glucosamide (OTG) [2], which provided prelimi-
nitrogen atom since, as shown earlier, C6-substitutednary information about the mode of binding of a glucose
glucose analogs behaved only as weak inhibitors [10];analog to the active site of the enzyme. Using this struc-
(3) in the yeast enzyme the glucose moiety is boundture as a scaffold, we have introduced modifications on
through an amidic bond to an aryl or an alkyl substituent,the substituent at the nitrogen atom of glucosamine and
resulting in its strong binding to the protein; therefore,have determined the respective affinities of the resulting
an aryl substituent was maintained; (4) the length of
the aryl substituent should be varied to optimize any4 Correspondence: willson@chimie.ups-tlse.fr (M.W.), sanejouand@
crpp.u-bordeaux.fr (Y.-H.S.) contacts with the protein; (5) the substituents on the
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aromatic ring should be varied with respect to their elec- Table 1. Inhibition Values IC50 (mM) for Glucosamine
tron releasing or withdrawing properties; and (6) the Derivatives on Hexokinase from Yeast and T. brucei
meta and ortho positions on the aromatic ring should
R Compounds Yeast T. brucei
be varied as well in order to explore the space within
C6H5 1 7 8the active site by ring rotation.
o-CH3-C6H4 2 8 6Here, we present parallel studies of the inhibitory ef-
o-NH2-C6H4 3 1 4.5fects by a series of glucosamine derivatives on both
m-NH2-C6H4 4 6 1.8
the yeast and T. brucei hexokinase. Because the three- o-NO2-C6H4 5 3 0.4
dimensional (3D) structure of the T. brucei hexokinase m-NO2-C6H4 6 6 2
o-Br-C6H4 7 – 3is not yet known, we have also inferred its structure by
m-Br-C6H4 8 – 0.5first cloning and sequencing its gene and by subse-
o-I-C6H4 9 – 4quently modeling its predicted amino acid sequence on
CH2Br 10 9 3the X-ray structure of Schistosoma mansoni hexokinase
CH2CH2Br 11 7 3
defined with 2.5 A˚ resolution [11]. From this model of
A dash indicates no effect at 20 mM. Each determination is donethe glucose-hexokinase complex, the position of the
in triplicate with SD  4%.inhibitor in the glucose binding site was inferred, and
the rebuilt model of the enzyme-inhibitor complex was
then compared with the X-ray structure of the complex
of yeast hexokinase-OTG as obtained by Steitz [2]. The extent of ADP formation relative to that of glucose phos-
analysis of different effects in terms of specific interac- phorylation. The inhibition kinetic data with respect to
tions between the noncarbohydrate moiety of the inhibi- glucose were calculated from Lineweaver-Burk plots
tors and the protein has then allowed us to identify the (1/v versus 1/glucose) with an intercept on the 1/v axis,
interactions responsible for the selective inhibition of T. at any concentration of the inhibitor. These compounds
brucei hexokinase. clearly competed for the substrate glucose by binding
at the active site. For the yeast enzyme, compounds 5
Results and 6 behaved as fully mixed-type inhibitors with two
inhibition constants Ki and Kii, the Ki value being lower
Inhibition of Enzymes than the Kii value. For the T. brucei enzyme, the inhibition
Table 1 summarizes the inhibitory effects of glucos- constants for compounds 2, 3, and 4 were in the range of
amine derivatives on glycosomal hexokinase from T. the Km value for glucose (110–120 M); for compounds
brucei and on hexokinase from yeast (Figure 3). Whereas bearing nitro or bromo substituents on the aromatic ring,
compounds 1 and 2 show similar effects on both en- the Ki values were considerably lower than the Km for
zymes, substituted derivatives exhibit different patterns. glucose (up to 40 times less for compound 8).
The most pronounced differences are observed with Since all compounds have an OH group at position 6
compounds 5 to 8, which carry an aromatic ring bearing of the carbohydrate moiety, they may theoretically serve
dipoles with external negative charges. A significant se- as pseudosubstrates for the enzyme and be phosphory-
lectivity is obtained with compound 8, since this com- lated by ATP-Mg. However, we have previously shown
pound has no effect at 20 mM concentration on the that phosphorylation by yeast hexokinase does not oc-
yeast enzyme, whereas its IC50 value for the T. brucei cur with this class of inhibitors, although they may in-
enzyme was 0.5 mM. duce hydrolysis of ATP by the enzyme [1, 12]. When
measuring ADP formation directly by the ATPase assay
involving the coupled PyK-LDH reaction, no activity wasKinetic Studies
observed for the T. brucei enzyme except with com-Table 2 gives the inhibition constants of the different
compounds determined for both enzymes and also the pound 5, which gave a relatively low rate of ADP produc-
Table 2. Inhibition Patterns of T. brucei and Yeast Hexokinases as Analyzed by Lineweaver-Burk Plots
ADP Formation (% Relative to Glucose-
Ki (M) Dependent Activity)
Compounds Y Tb Y Tb
1 C 1000  9 5 –
2 (oCH3) C 1000  8 C 100  1 6 –
3 (oNH2) C 280  3 C 105  2 34 –
4 (mNH2) C 200  1 C 114  4 15 –
5 (oNO2) MT Ki 500  4 C 19  0.5 28 6
Kii 900  8
6 (mNO2) MT Ki 450  1 C 8  0.2 9 –
7 (oBr) C 25  0.6 –
8 (mBr) C 2.8  0.1 –
9 (oI) C 100  1 –
10 C 1100  7 C 70  1 – –
11 C 1200  6 C 30  0.5 – –
Tb, T. brucei; Y, yeast; C, competitive inhibition; MT, mixed-type inhibition; dash, no ADP formation detected.
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Figure 1. Comparison of the Amino Acid Sequences of the Hexokinase of T. brucei with Corresponding Protein of Other Organisms: Yeast,
Schistosoma mansoni, and Three Human Hexokinase
The sequences were aligned for maximal positional identity using the GCG-Pileup software. The alignment is slightly different from the one
used for the modeling. Differences are located in the vicinity of the insertions/deletions, far away from the binding site.
tion. By contrast, compounds 1 to 6 induced a significant 51,189 and the pI is 9.11. This corresponds reasonably
well with the measured values of 50,300 Da and pI 10.2,rate of ATP hydrolysis by the yeast enzyme.
respectively. The amino acid sequence of the T. brucei
enzyme was aligned with that of some other organismsCloning and Sequence Determination
(Figure 1). Only a very low percentage of sequence iden-of the T. brucei Hexokinase Gene
tity was observed in the pairwise comparison of theInitial attempts to identify the hexokinase gene of T.
trypanosome hexokinase with each of its counterpartsbrucei by hybridization with hexokinase genes of some
used in this analysis: 30% with yeast hexokinase (isoen-other organisms as probe were unsuccessful, indicating
zyme B) and 37% with both the Schistosoma mansonia large divergence between the gene of the trypano-
enzyme and the human brain hexokinase (isoenzyme I).some and that of these different organisms. A different
Our trypanosome gene sequence agrees with those ofapproach was thus taken. The enzyme was purified from
the various fragments covering only part of the full-T. brucei glycosomes, subjected to acid hydrolysis, and
length hexokinase gene, as available (September, 2001)some peptide fragments thus obtained were sequenced.
in the database of the T. brucei genome project.The peptide sequences provided us the information to
amplify by PCR a genomic fragment that, after sequence
analysis, could be used to clone the entire hexokinase Modeling Studies with Compound 8
Ten crystallographic structures of hexokinase are pres-gene. The polypeptide encoded by the gene contains
474 amino acids. The calculated molecular mass is ently (September, 2001) available in the Protein Data
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Bank. Six of them are mammalian hexokinases, with a Table 3. Van der Waals Interactions between the
molecular weight nearly twice (100,000 Mr) that of T. m-bromophenyl Part of Inhibitor 8 and T. brucei-Hexokinase
brucei (50,000 Mr). Among the four remaining ones, three (from Model Building)
are structures of yeast hexokinase, but the most recent Phenyl Atoms Contacts  3 A˚ Distances (A˚)
one (1IG8) was determined in a free, open form, while
C*7 Gln300 (NH)b 2.58the two others were determined when the actual poly-
C*2 Gln300 (NH)b 2.64peptide sequence was still unknown [13, 14]. Since only
C*3 Gln300 (NH)b 2.78
30% of the amino acid sequence as inferred from these C*1 Gln300 (C  O)b 2.87
crystal structures agreed with the actual residues as C*5 Arg176 (NH) 2.74
Arg176 (N) 2.81deduced later from the gene sequence, these structures
Gln300 (C  O)b 2.84would be the wrong starting point for our modeling stud-
C*6 Gln300 (C  O)b 2.75ies. Therefore, we decided to use the structure of the
50,000 Mr hexokinase from Schistosoma mansoni (PDB The numbers and asterisks on carbon atoms are those from the
Protein Data Bank for OTG-yeast hexokinase complex (2). b,code 1bdg) [11], which is available at 2.5 A˚ resolution,
backbone.while its sequence shares 36% of identical residues
with the T. brucei sequence (Figure 1). This allows an
accurate modeling with standard protocols, especially
in the neighborhood of the conserved substrate binding
amino acid side chains far away from the binding site,
site. Furthermore, this structure is available as a com-
the backbone, the glucose derivative, and the side
plex with its substrate glucose; the location of the sub-
chains surrounding it (less than 4 A˚ away) were held
strate within the active site can be used as a starting
fixed, and another 120 psec MD simulation was per-
point for the positioning of glucose derivatives, as done
formed. Finally, in order to relax the aromatic ring of the
earlier in the case of the yeast hexokinase [13, 14], an
compound and the side chains in its vicinity, the sugaradvantage which was exploited in our previous model-
moiety and the protein backbone were held fixed, asing study as well [1]. The T. brucei sequence was first
well as all atoms more than 8 A˚ away from the glucosemodeled on the 3D structure of the S. mansoni hexoki-
derivative, a last 320 psec MD simulation was per-nase using protein modeling server SWISS MODEL [15–
formed, and the average structure obtained over the17] developed at Glaxo-SmithKline in Geneva (http://
last 200 psec of this simulation was retained for furtherwww.expasy.ch). Due to ambiguities in the alignment of
analysis.the first 59 and the last 4 amino acid residues of the T.
Tables 3 and 4 and Figure 2 give a detailed analysisbrucei sequence with that of S. mansoni, these residues
of interactions with a listing of Van der Waals contactscould not be included in the model. It was assumed that
and hydrogen bonds between the m-bromophenyl partthe positioning of the glucose moiety in the active site
of inhibitor 8 and the T. brucei hexokinase from modelof the structure of the S. mansoni hexokinase-glucose
building.complex and that of the glucose derivatives considered
in the present study would be identical. Next, whether
the aromatic ring and the peptidic bond are roughly
In Vitro Activitiescoplanar in the case of m-compounds similar to our
The activity of the different compounds on growing,analogs was checked in the Cambridge Structural Data-
in vitro cultured T. brucei cells was assayed at 5 mMbank, and this was enforced hereafter by adding the
concentration. A significant correlation was found be-corresponding “improper” term in their topological de-
tween the affinity of a given compound for T. bruceiscription for the Charmm program [18]. Thus, only two
hexokinase and the biological activity on cultures: fordegrees of freedom remained for the positioning of glu-
nitro and bromo compounds 5, 6, and 7 at 5 mM concen-cose derivative 8 in the active site of the T. brucei hexoki-
tration, the percentage of inhibition was 34%, 59%, andnase: first, the dihedral angle around the C2-N2 bond
25%, respectively. Again, compound 8 was the mostand second, the cis or trans location of the m-bromine
effective, completely inhibiting growth at a dose of 3.6atom (o-bromine was not considered here because, due
mM even in the presence of a competing concentrationto steric effects, it was expected to disrupt the coplanar-
of 5 mM glucose in the cultures, a concentration which isity between the aromatic ring and the amidic bond in
similar to that prevailing in the mammalian bloodstream.a manner difficult to predict accurately with empirical
forcefields). To determine the importance of the two cis/
trans conformations, each possibility was considered in
a separate modeling study which was performed ac-
Table 4. Hydrogen Bonds between the m-bromophenyl Part of
cording to the protocol described below. Inhibitor 8 and T. brucei Hexokinase’s Binding Site (from
First, water molecules with bulk water density were Model Building)
added to the T. brucei hexokinase-glucose derivative
Donors (X) Acceptors (Y) X  Y (A˚)
complex, such that they all lay less than 8 A˚ away from
Br (HN)b-trp177 2.89the protein. Then, in order to let the solvent relax, espe-
Br (HN)b-Thr178 3.22cially within the well-structured and high-density first
C*4 HN-terminal Arg176 2.74water shell around the protein [19], the complex was
C*4 HN-intra Arg176 2.89
held nearly fixed using harmonic restraints, and a short Thr178  OH HN  C2 2.32
10,000 conjugate gradient energy minimization step was Gln300  NH2 O*7 2.18
performed, followed by a 120 psec molecular dynamics
b, backbone.
(MD) simulation at T  300 K. Next, in order to relax the
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Figure 2. A Model of the T. brucei Hexoki-
nase-Glucose Derivative Complex
These figures were made with Molscript.
(A) Predicted 3D structure of hexokinase-in-
hibitor 8 complex. Green represents the car-
bon chain and orange-brown represents the
inhibitor 8.
(B) Complex of N-(m-bromophenyl) glucos-
amine 8 in the Trypanosoma brucei substrate
binding site from model building (ball and
stick represents the protein).
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kinase in complex with the m-bromine derivative 8
allows us to understand why the latter acts as a selective
inhibitor. When the bromine atom is in the cis position
with respect to the oxygen of the carbonyl group, the
average interaction energy between the glucose deriva-
tive and the protein is 17 kcal/mole higher than when it
is in the trans position. This trans conformer seems to
fit the active site of T. brucei hexokinase much better
than the cis conformer. For this reason, we only consider
the trans conformer. When the model of the T. brucei
hexokinase-m-bromine derivative complex thus ob-Figure 3. General Structure of the Inhibitors of Hexokinase
tained is compared with our previous model of the yeastR is as described in Table 1.
hexokinase-OTG complex, some clear differences are
observed. First, while in both cases the glucose moiety
Discussion and the amidic bond are roughly perpendicular and in
the same relative configuration, the positioning of the
A comparative study in which a set of glucosamine deriv- aromatic ring is different. In the case of OTG, the aro-
atives was tested in activity assays carried out with matic ring and the amidic bond are almost perpendicu-
hexokinase of both yeast and the parasite T. brucei lar, which is likely to be due to the fact that OTG is an
allowed us to draw the following conclusions. First, with ortho-substituted derivative, where steric effects can
the exception of reference compound 1, which contains compete with electronic delocalization. By contrast, in
an unsubstituted ring, the affinities of all compounds compound 8 the aromatic ring and the amidic bond are
were higher for the parasite than for the yeast hexoki- coplanar. Second, most of the amino acids found in the
nase. All compounds behaved as full competitive inhibi- direct neighborhood of the two glucose derivatives are
tors with respect to glucose, with Ki values for T. brucei highly conserved, but the pattern of interactions is differ-
hexokinase ranging from the Km value for glucose (Km ent in both complexes, especially in the vicinity of the
120 M) to significantly lower values (e.g., nitro and aromatic ring. The bromine atom interacts only with the
bromo derivatives). Molecules bearing the bulky nitro side chains of Arg176, Thr178, and Gln300 (Figure 2),
substituent gave a mixed-type inhibition but only with which are all conserved in T. brucei and the yeast se-
the yeast hexokinase. Since several glucose-enzyme quences (Figure 1) (respectively, Arg153, Thr155, and
complexes with different enzymic conformations have Gln280 in our previous yeast hexokinase model). Note
been described for the latter enzyme [20], we assume that these three residues are also conserved in the S.
that for our present compounds several inhibitor-hexo- mansoni hexokinase sequence. Interestingly, Arg176 is
kinase complexes [1] may exist simultaneously, provid- replaced by Thr or Ser in the various human isoforms of
ing an explanation for the observed mixed-type inhibi- hexokinase, supporting the underlying hypothesis that
tion. Such different conformations do probably not play some well-chosen m-derivative compounds may prove
a role in the parasite enzyme since only a fully competi- to be specific inhibitors of nonhuman hexokinases. Fur-
tive inhibition was observed, suggesting that a single thermore, the close proximity of both the terminal and
or predominant form of the protein interacts with the internal NH of Arg176 to the aromatic ring allows a posi-
inhibitor to give a single EI complex. tive charge  electron interaction between the inhibitor
Second, brominated molecules are the best inhibitors. and the arginine residue. Such hydrogen bonds are ener-
Different affinities were found for aliphatic and aromatic getically significant in water (5 Kcal/mole) [21] and can
inhibitors. The Ki/Km ratio is 0.6 and 0.2 for bromomethyl account for the high affinity (Ki  2.8 M) of compound
10 and bromoethyl 11 glucosamide, respectively, 8. Such a tight interaction may also be responsible for
whereas this ratio decreased to 0.02 for the bromophe- bringing the two lobes of the enzyme in close contact,
nyl glucosamide 8. Moreover, the three halogeno-aryl so inducing the closed conformation of the protein. As
derivatives 7, 8, and 9 are selective for the parasite far as the better affinity of compound 8 for the T. brucei
enzyme without any effect on the yeast enzyme. enzyme with respect to the yeast one is concerned,
Third, no ADP formation was detected for any of the given the virtually perfect conservation of most residues
inhibitors tested as potential substrates for T. brucei lying in the binding site, the only reasonable explanation
hexokinase. In contrast, we have demonstrated pre- we found is along the following line: the C atom of
viously [5, 12] by using NMR and infrared spectroscopy Arg58 is 6 A˚ away from the aromatic ring of compound
that yeast hexokinase in the presence of aromatic inhibi- 8. Through there is no direct interaction between the
tors adopts an open conformation that enhances hydro- end of the side chain of Arg58 and the aromatic ring in
lysis of ATP bound in the active site, whereas aliphatic our model, such an interaction is geometrically possible.
inhibitors 10 and 11 induce a conformation of the protein Anyway, it is the only significant difference between the
similar to the glucose-hexokinase complex. As a conse- two binding sites in the vicinity of the aromatic ring of
quence, no ATP hydrolysis was observed. The different compound 8 (in yeast, there is a Pro residue in the
behavior of the two proteins suggests to us that in the corresponding position).
presence of our set of inhibitors, the parasite enzyme Finally, there exists a clear correlation between the
always adopts a closed conformation, whereas the respective affinities of our inhibitors for the T. brucei
yeast enzyme does not always. hexokinase and their lethal effect on cells. The LD50
values are in the range of 5–10 mM for inhibitors 5, 6,Fourth, modeling of the 3D structure of T. brucei hexo-
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and 7. The best inhibitor, 8, is also the most toxic to the of yeast hexokinase, it was possible to design a first
series of compounds. To obtain selectively criteria forparasite in in vitro culture with a LD100 of 3.6 mM. This
dose is relatively high, but this may be due to the fact inhibition of the parasite hexokinase, the enzyme was
cloned and selective inhibitors could be thus charac-that glucose, present in the culture medium at a concen-
tration of 5 mM, competes with the drug for the active terized. Their selectivity was rationalized by modeling
the inhibitor-enzyme complex based on another para-site of the enzyme. In a separate study, we have mea-
sured the affinities of compounds 3 to 8 for the T. brucei site hexokinase structure. It is shown that this selec-
tivity is provided by a proper orientation of the aro-glucose transporter (THT1) which is responsible for the
facilitated diffusion of glucose into the parasite [22]. Our matic ring attached at the glucose moiety, to make a
-NH3R interaction with Arg176. This residue, in-compounds displayed no affinity for this transporter and
therefore they most likely enter the trypanosome by pas- volved in the binding, only exists in the parasite en-
zyme. On these grounds, it should now be possible tosive diffusion rather than by accumulation against a con-
centration gradient via a mechanism of active transport. design more potent irreversible and specific inhibitors
exploiting this amino residue as a covalent linker.Therefore, the intracellular concentration of the inhibi-
tors will most likely not exceed their extracellular con-
centration. Experimental Procedures
Our inhibition studies, in combination with the model-
Source of Enzymes, Substrates, and Cofactorsing of one of our compounds inside the active site of
Yeast hexokinase, glucose, ATP, NADH, NADP	, phosphoenolpyr-the T. brucei hexokinase, have provided insight into the
uvate (PEP), the linking enzymes glucose-6-phosphate dehydroge-mode of action of the class of glucosamine analog inhibi-
nase (G6PDH), pyruvate kinase (PyK), and lactate dehydrogenase
tors. Moreover, from this work a number of suggestions (LDH) were purchased from Roche (Germany). The hexokinase from
for improvement of such inhibitors can be proposed. T. brucei was purified as described by Misset et al. [8].
First, we expect more potent inhibitors from the replace-
ment of the bromo substitutent by strongly electron- Synthesis of Inhibitors
donating groups, which would ensure the same orienta- The pure compounds were identified by spectrometric analysis on
apparatus of the Institute of Molecular Chemistry Paul Sabatiertion of the aromatic ring toward Arg176 and would en-
(ICMPS-IR1744). IR spectra were recorded on a Perkin-Elmer FTIRforce the NH- electron interaction by increasing the
1610 spectrometer, 1H and 13C NMR spectra were run on a Bruker density. A lethal dose of 3.6 mM of 8 predicts that
250MHZ FT apparatus, and mass spectra were determined on aglucosamine analogs which behave as competitive in-
Nemag R10-10.
hibitors will not be very effective in vivo, because they The synthesis of compounds 1–7 was achieved as described in
have to compete with the high concentration of glucose Willson et al. [1]. For compounds 8–11, the general procedure for
their synthesis was a coupling reaction between the unprotectedin the blood of the host. In order to become interesting
D-glucosamine hydrochloride and the appropriate p-nitro-phenylas lead compounds, the affinity of such glucosamine
esters [24] under stoichiometric conditions at room temperature inanalogs for the enzyme would have to be increased by
dimethylsulfoxide (DMSO). In the preceding step, the p-nitrophenyla 100- to 1000-fold. Second, the problem of low affinity
esters were prepared by reaction of p-nitrophenol with the halide of
for the glucose binding site and the competition for carboxylic acids : 3-bromobenzoyl chloride, 2-iodobenzoyl chloride,
it by glucose could be overcome by the synthesis of bromoacetyl bromide, and 3-bromopropionyl chloride. Before the
coupling reaction, the glucosamine hydrochloride was neutralizedirreversible inhibitors. This would result in a potent
with a tertiary organic base (triethylamine) in DMSO. The productsmechanism for the inactivation of the enzyme. Such
were subsequently extracted from the DMSO solution by precipita-inhibitors should exploit the presence of residue Arg176,
tion with dichloromethane. They were purified by recrystallizationwhich is specific for the T. brucei enzyme with respect
from a large volume of ethanol. The atom numbering used in Tables
to human the one, ideally by carrying electrophilic cen- 3 and 4 is as that in the Protein Data Bank for the OTG-yeast hexoki-
ters that could interact with this residue. Finally, one nase complex [2].
N-(m-bromobenzoyl)-D-glucosamine 8could envision the synthesis of glucosamine analogs
Yield  60%. TLC (eluent ethanol) Rf  0.75. IR (pellet) 
 cm1 1632that would enter the cell via a mechanism of active
(C  O). 1H NMR (DMSO-D6);  (ppm) 6.75 (d, NH, J  6.3Hz), 5.74transport. While the trypanosome THT1 transporter is a
(C1H, J  4.5Hz). 13C NMR (DMSO-D6);  (ppm) ( and  forms):facilitated diffusion carrier and does not recognize this
56.3-58.1 (C2), 61.4 (C6), 70.10-71.0 (C3), 71.2-74.1 (C4), 72.1-76.9
class of compounds, other trypanosomatids, including (C5), 91.3-96.3 (C1), 128.1 (C*4), 118.0 (C*6), 130.2-129.3 (C*3-C*1),
Trypanosoma cruzi and Leishmania, have active carriers 131.6-132.0 (C*5), 134.4-134.9 (C*2), 167.3-167.5 (C*7). Mass: (FAB),
MH	, 361; MNa	, 384.for glucose [23] which are able to concentrate glucose
N-(o-iodobenzoyl)-D-glucosamine 9against a considerable concentration gradient. Such in-
Yield  72%. TLC (eluent ethanol) Rf  0.85. IR (pellet) 
 cm1 1672hibitors might find their use in the treatment Chagas’
(C  O). 1H NMR (DMSO-D6);  (ppm) 6.62 (d, NH, J  6.1Hz), 5.80disease and Leishmaniasis.
(C1H, J  4.3Hz). 13C NMR (DMSO-D6);  (ppm) ( and  forms):
59.3-56.5 (C2), 62.9 (C6), 72.5 (C3), 72.4-76.0 (C4), 72.2-76.1 (C5),
92.5-97.0 (C1), 92.5 (C*1), 129.1-129.3 (C*4), 129.3-129.4 (C*3), 132.0
Significance (C*6), 140.8-141.0 (C*5), 144.1 (C*2), 172.6 (C*7). Mass: (DCI), MH	,
408; MNH4	, 425.
N-(bromo-acetyl)-D-glucosamine) 10Owing to the lack of cheap and efficient drugs against
Yield  48%. TLC (eluent ethanol) Rf  0.60. IR (pellet) 
 cm1 1712sleeping sickness, it is essential to develop new leads
(C  O). 1H NMR (DMSO-D6);  (ppm) 6.82 (d, NH, J  6.2Hz), 4.25based on the inhibition of specific metabolisms for the
(s, CH2Br). 13C NMR (DMSO-D6);  (ppm) ( and  forms): 44.8-44.9
parasite. Glycolysis meets this requirement since it (C8), 57.0-59.7 (C2), 63.1-63.3 (C6), 72.4-72.6 (C3), 73.2-74.1 (C4),
represents the exclusive source of energy for the para- 76.1-78.5 (C5), 93.2-97.1 (C1), 172.6-172.9 (C7). Mass (DCI), MH	,
301; MNH4	, 317.site in the bloodstream form. Using the 3D structure
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N-(bromo-propionyl)-D-glucosamine 11 Possible interference of the inhibitors with the absorbance of
NADPH or NADH was verified by running blank reactions withoutYield  54%. TLC (eluent ethanol) Rf  0.60. IR (pellet) 
 cm1 1720
(C  O). 1H NMR (DMSO-D6);  (ppm) 6.78 (d, NH, J  5.9Hz), 2.32 enzyme. The remaining activity was calculated from comparison
with control experiments in which the inhibitor was replaced by the(t, CH2 CO), 3.10 (t, CH2Br). 13C NMR (DMSO-D6);  (ppm) ( and 
forms): 30.1-30.3 (C8), 40.9-41.4 (C9), 56.6-59.3 (C2), 63.0-63.22 (C6), same amount of the solvent DMSO; at a solvent concentration in
the buffer below 10%, no significant effect on the enzyme activity72.3-72.5 (C3), 73.1-76.2 (C4), 76.3-78.4 (C5), 93.3-97.3 (C1), 176.1-
176.4 (C7). Mass (DCI), MH	 314; MNH4	 331. was observed. The concentration of inhibitor required for 50% inhi-
bition (IC50) was calculated from at least 5 inhibitor concentrations;
they were tested with substrates present at saturating concentra-Cloning and Sequencing of T. brucei Hexokinase Gene
tions. The type of inhibition and the inhibition constant (Ki) werePeptides of purified glycosomal hexokinase were prepared by acid
determined from Lineweaver-Burk plots. The inhibition with respecthydrolysis [25] and purified. Seven of the peptides were sequenced
to glucose was studied at three different concentrations of glucoseby classical automated Edman degradation, but only two could be
(100 M, 200 M, and 300 M) at a saturating concentration ofaligned with amino acid sequences of hexokinases from various
ATP (0.66 mM). To determine whether the compounds could beorganisms (peptide 1, LNRTVPLGFTFSFP?VEQTKVNRGVLIRFTK
phosphorylated by the enzyme at the expense of ATP, we measuredH?FS?L?; peptide 2, TVGTLISHYFKAI?KEGAV). Based on these se-
the amount of ADP formed in the presence of 10 mM of the inhibitorquences, a sense primer 5-CGCGGATCCGTNGARCARACNAARG
as a substrate, without glucose, relative to the amount of ADP pro-TNAA-3 and an antisense primer 5-CGCGGATCCTCYTTDATNG
duced with only 10 mM of glucose.CYTTRAARTA-3 containing BamH1 sites (underlined) were de-
signed and used for PCR amplification with purified genomic DNA
as template. Several DNA fragments were obtained. After sequenc-
Molecular Modeling and Molecular Dynamicsing, one of the clones, with an insert of approximately 200 bp (corre-
The Charmm program [18], version 24, was used in order to performsponding to residues 164–226 in the T. brucei amino acid sequence),
all structural optimizations. Nonbonded interactions were calculatedappeared to have hexokinase-specific motifs and was used to
using a 7.5 A˚ cutoff, a shifting function for electrostatics as wellscreen a genomic library of T. brucei in Escherichia coli prepared
as a switching function for Lennard-Jones interactions, within awith the vector GEM11 (Promega, USA) as described previously
6.5–7.5 A˚ distance range. All distances between bonded atoms were[26]. Plaques of positive clones were processed, the DNA was puri-
constrained, using the SHAKE algorithm, allowing for the use of afied, and an appropriate restriction fragment containing the hexoki-
0.002 psec time step in order to integrate the equations of atomicnase gene was subcloned in the phagemid pTZ18R (Amersham-
motion. The temperature was controlled through the coupling of thePharmacia Biotech, Sweden). DNA sequence determination was
system to an external thermal bath, mimicked by Langevin forcesperformed on both strands by the chain-termination method using
acting on all atoms, with a 1.5 ps1 friction constant.the T7 DNA polymerase kit of Amersham-Pharmacia Biotech with
double-stranded DNA as template, [35S]dATP (PerkinElmer Life Sci-
ences, USA), and specific, custom-made oligonucleotides (In-
Measurement of Antitrypanosomal Activity In Vitrovitrogen/Life Technologies, UK) as primers.
T. brucei bloodstream forms were cultured in vitro in a modified
Iscove’s medium containing 10% heat-inactivated fetal calf serumAssay of Enzyme Activities
(HI-FCS) and bloodstream form supporting factors 0.05 mM batho-The phosphotransferase activity and the consumption of ATP were
cuproine sulfonate, 1.5 mM L-cysteine, 1 mM hypoxanthine, 0.2 mMmeasured spectrophotometrically by reduction of NADP	 or oxida-
2-mercaptoethanol, 1 mM sodium pyruvate, 0.16 mM thymidine (HMItion of NADH in the coupled assays shown in the following equa-
9) [27]. Cells were incubated in a humidified atmosphere containingtions.
5% CO2 at 37C. The effect of the compounds was tested essentially
Method A: as described by Freiburghaus et al. [28]. Compounds were initially
dissolved in DMSO and/or water and diluted with the medium. Aque-
ous solutions were sterilized by filtration before being diluted. TheG 	 ATP-Mg→HKG6P 	 (ADP-Mg) 	 NADP →G6PDH NADPH 	
highest concentration of DMSO after serial dilution with complete
phospho-gluconolactone culture medium was 1%. Each compound was tested in duplicate
in 96-well microtiter plates in 3-fold serial dilutions. Fifty microliters
Method B: of a cell suspension in complete medium (5 104cells/ml) was added
to each well. After incubation for 72 hr, each plate was examined
with an inverted microscope to determine the minimum inhibitoryATP-Mg 	 G→HK(G6P) 	 ADP-Mg 	 PEP →PyKATP-Mg 	
concentration (MIC), which is the concentration at which no cell
with a normal morphology and/or motility is found in comparisonlactate 	NAD →LDHNADH 	 pyruvate
to the control. Afterwards, Alamar Blue was added into each well
to reach a final concentration of 5%, and the plates were incubated
for 4 hr before viability was determined using a cytofluorimeterKinetic Studies
(Millipore Cytofluor 2300, Millipore, USA). The excitation wavelengthThe inhibition of hexokinase by compounds was measured by
was 530 nm, and the emission wavelength was 590 nm. Controlassaying the enzyme activity in the direction of NADPH and NADH
wells without inhibitor were included as well as blanks without cells.formation; the concentration of the cofactors was calculated from
their absorbance using an 340  6.22 mM1cm1. All reactions were
carried out at 25C, and the formation of NADH or NAD	 at 340
Acknowledgmentsnm was measured with a PerkinElmer spectrophotometer equipped
with a kinetic accessory unit. The activities of the compounds on
This research was financially supported by the European-Unionhexokinase were measured after 5 min of preincubation of the en-
(contrat IC18-CT970220) and GDR-CNRS-GGA 2177, which are bothzyme with the compound in the assay buffer, followed by addition
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Brussels) for his assistance in the enzyme purification, Mme. Chris-For the phosphotransferase activity (method A), the reaction mix-
tiane Vidal for assistance in the modeling study, and Paul A.M.ture (1 mL) contained 0.1 M triethanolamine hydrochloride buffer
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